Sunnybrook Hospital, University of Toronto, Canada
Julie Lovshin is a clinical investigator with research interests in the complications of diabetes, with a specific focus on systemic and renal hemodynamic function.
Dr. Lovshin obtained her PhD from the University of Toronto under the supervision of Dr. Daniel Drucker, studying the molecular biology of GLP-2 (a gastrointestinal peptide that promotes growth & protection of the GI tract) and GLP-2 receptor signalling and related gastrointestinal hormones (GLP-1, oxyntomodulin) in the periphery and CNS. Following her PhD, she completed medical school, with specializations in internal medicine and endocrinology and metabolism at the University of Toronto.
Dr. Lovshin then completed a four-year post-doctoral research fellowship in the Clinical Investigator Program and Clinician Scientist Research Training Program at the University of Toronto carrying out mechanistic clinical investigation primarily on non-glycemic effects of incretin-based diabetes therapies and SGLT-2 inhibitors. During this time, she completed the certificate program in Clinical Research Methods in Biostatistics and Clinical Epidemiology at the Harvard School of Public Health and Brigham and Women's Hospital, Harvard University, Boston, MA where she examined screening rates for diabetic retinopathy in Ontario with Dr. Baiju Shah. Dr. Lovshin developed research expertise in renal hemodynamic function working closely with Dr. David Cherney (nephrology), and also on the Canadian Study for Longevity in Diabetes with Bruce Perkins and colleagues.
Research Support: Novo Nordisk, Merck Canada, Sanofi Canada
Consultant: AstraZenca, Boehringer Ingelheim, Eli Lilly & Co, Intarcia, Therapeutics Inc, Merck, Novo Nordisk, Prometric